Advertisement
Canada markets open in 4 hours 7 minutes
  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     
  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     
  • DOW

    37,903.29
    +87.37 (+0.23%)
     
  • CAD/USD

    0.7292
    +0.0010 (+0.14%)
     
  • CRUDE OIL

    79.72
    +0.72 (+0.91%)
     
  • Bitcoin CAD

    79,271.13
    +878.52 (+1.12%)
     
  • CMC Crypto 200

    1,267.47
    -3.27 (-0.26%)
     
  • GOLD FUTURES

    2,313.80
    +2.80 (+0.12%)
     
  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     
  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     
  • NASDAQ futures

    17,571.25
    +133.00 (+0.76%)
     
  • VOLATILITY

    15.05
    -0.34 (-2.21%)
     
  • FTSE

    8,146.06
    +24.82 (+0.31%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6809
    +0.0016 (+0.24%)
     

Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024

BRANFORD, Conn., April 18, 2024--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the first quarter 2024 on Thursday, May 9, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET.

Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations.

Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.

ADVERTISEMENT

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418068472/en/

Contacts

Investor Contact
Jeff Keyes, Chief Financial Officer
ir@quantum-si.com

Media Contact
Katherine Atkinson, SVP of Commercial Marketing
media@quantum-si.com